Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

Leukotriene receptor antagonists represent potent antiasthmatic drugs that have been extensively evaluated in clinical trials in patients (pts) with persistent asthma. There is now incresing tendency to evaluate antiasthmatic drugs in terms of effectiveness, meaning efficacy plus patient adherence, drug safety and costs. The aim of our study was to compare montelukast and inhaled corticosteroids (beclomethasone) in persisting asthma in a "real world " setting. We studied 78 adults with mild and moderate asthma, aged between 18-75, 48 females and 30 males, 39 treated with montelukast and 39 with beclomethasone dipropionate, during three months.The study was opened labeled with pts self selection, treated according to GINA recommendations.Daily and night symptoms score and FEV1 were measured before and at the end of the study, preference for oral or inhaled therapy ,opinion about treatment, safety profile and cost were recorded. Improvement of symptoms scores and FEV1 did not significantly differ between groups (NS). No preference for oral therapy was recorded . Safety profile was favorable and similar for both groups. Treatment was considered efficient by 67 % pts in montelukast group and by 73% in beclomethasone one, moderate efficient by 28 % and 23 % respectively. 8 % pts considered montelukast not efficient. Treatment costs and pts expectation were much higher for montelukast, causing the impossibility to continue after 3 months in 50 % pts. We concluded that cost-effectiveness profile and pts global satisfaction are better for inhaled corticotherapy, with no preference for oral therapy in adult asthmatics.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Leru, C. Baicus, D. Gologanu (Bucharest, Romania). Considerations about cost-effectiveness and global satisfaction of asthmatic patients treated with montelukast compared with inhaled corticosteroids. Eur Respir J 2002; 20: Suppl. 38, 384

Member's Comments

No comment yet.

Related content which might interest you: Long-term safety of inhaled formoterol in adult asthma patients Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 The comparative assessment of quality of life in asthma patients treated with inhaled steroids Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002 Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Once per day inhaled corticosteroids: a method to improve compliance and asthma control Source: Eur Respir J 2001; 18: Suppl. 33, 441s Year: 2001 Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007 As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003 Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006